Ankita Agrawal

About

After graduating from Delhi University, India with a BSc (Zoology) and The University of Sheffield, UK with an MSc (Stem Cell and Regenerative Medicine), I was a research technician in Dr Alison Gartland's lab at the Mellanby Centre for Bone Research (Sheffield, UK) for 2 years. Under her mentorship, I completed my PhD detailing the involvement of purinergic signalling in osteoclastogenesis. I subsequently moved back to my home country as a research associate at CSIR- IGIB (Delhi) investigating the genetic determinants in chronic pancreatitis- but it is in Denmark (Bone Lab, Rigshospitalet) that I have been able to both, continue in the purine field and combine it with my interest in bone health and metastasis.

Employment

• Rigshospitalet Senior Scientist
  2021 - Present
• Rigshospitalet Post Doc
  2016 - 2021
• Rigshospitalet Post Doc
  2014 - 2015
• Institute of Genomics and Integrative Biology CSIR Research Associate
  2013 - 2014
• University of Sheffield Medical School Research Technician
  2008 - 2010
• The Capital Region of Denmark

Education

• University of Sheffield PhD
  2010 - 2013
• University of Sheffield MSc Stem Cells and Regenerative Medicine
  2007 - 2008
• Hansraj College B.Sc. (Hons.)
  2004 - 2007

Projects & Funding

Projects & funding information is unavailable.

Publications (24)

• A step-by-step protocol based on data mining to explore purinergic signaling in glioblastoma
  Purinergic Signalling 2025 DOI: 10.1007/s11302-025-10080-z
  +Save
• Preclinical and clinical aspects of P2X receptors as a common route in different diseases
  Purinergic Signalling 2024 DOI: 10.1007/s11302-024-09994-x
  +Save
• EU COST Action CA21130 PRESTO 'P2X receptors as therapeutic targets' inaugural meeting report
  Purinergic Signalling 2023 DOI: 10.1007/s11302-023-09954-x
  +Save
• Expression of the Purinergic P2X7 Receptor in Murine MOPC315.BM Myeloma Cells
  Receptors 2023 DOI: 10.3390/receptors2030013
  +Save
• Absence of P2Y2 receptor does not prevent bone destruction in a murine model of muscle paralysis-Induced bone loss
  Frontiers in Endocrinology 2022 DOI: 10.3389/fendo.2022.850525
  +Save
• Discovery of thymosin β4 as a human exerkine and growth factor
  American Journal of Physiology: Cell Physiology 2021 DOI: 10.1152/ajpcell.00263.2021
  +Save
• Extracellular purines and bone homeostasis
  Biochemical Pharmacology 2021 DOI: 10.1016/j.bcp.2021.114425
  +Save
• Human P2X7 Receptor Causes Cycle Arrest in RPMI-8226 Myeloma Cells to Alter the Interaction with Osteoblasts and Osteoclasts
  Cells 2020 DOI: 10.3390/cells9112341
  +Save
• P2X7 receptor regulates osteoclast function and bone loss in a mouse model of osteoporosis
  Scientific Reports 2018 DOI: 10.1038/s41598-018-21574-9
  +Save
• Bone turnover is altered in transgenic rats overexpressing the P2Y2 purinergic receptor
  Purinergic Signalling 2017 DOI: 10.1007/s11302-017-9582-3
  +Save